Literature DB >> 35859870

Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.

Shefali Chowdhary1, Joel Mosnier2,3,4,5, Isabelle Fonta2,3,4,5, Bruno Pradines2,3,4,5, Nosipho Cele6, Pule Seboletswe6, Parvesh Singh6, Vipan Kumar1.   

Abstract

In the search of new antiplasmodial agents, a multitargeted approach was used in the synthesis of triazolopyrimidine- and 4-aminoquinolines-based hybrids. In vitro antiplasmodial evaluation on chloroquine-sensitive (3D7) and -resistant (W2) P. falciparum strains identified triazolopyrimidine-4-aminoquinoline hybrids to be the most potent in the series, outperforming bis-triazolopyrimidines. The active compounds were subjected to mechanistic studies with the plausible and expected targets including heme, PfCRT, and PfDHODH, that eventually validated the biological data. The active compound surpassed the antimalarial drug CQ by inhibiting the parasite's cellular process (hemozoin formation) and parasitic enzymes (PfCRT and PfDHODH), as confirmed by UV-vis and molecular modeling studies.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35859870      PMCID: PMC9290004          DOI: 10.1021/acsmedchemlett.2c00078

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  36 in total

1.  Mapping antimalarial pharmacophores as a useful tool for the rapid discovery of drugs effective in vivo: design, construction, characterization, and pharmacology of metaquine.

Authors:  Michael J Dascombe; Michael G B Drew; Harry Morris; Prapon Wilairat; Saranya Auparakkitanon; Wendy A Moule; Said Alizadeh-Shekalgourabi; Philip G Evans; Michael Lloyd; Anthony M Dyas; Pamela Carr; Fyaz M D Ismail
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

2.  A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.

Authors:  Margaret A Phillips; Karen L White; Sreekanth Kokkonda; Xiaoyi Deng; John White; Farah El Mazouni; Kennan Marsh; Diana R Tomchick; Krishne Manjalanagara; Kakali Rani Rudra; Grennady Wirjanata; Rintis Noviyanti; Ric N Price; Jutta Marfurt; David M Shackleford; Francis C K Chiu; Michael Campbell; Maria Belen Jimenez-Diaz; Santiago Ferrer Bazaga; Iñigo Angulo-Barturen; Maria Santos Martinez; Maria Lafuente-Monasterio; Werner Kaminsky; Kigbafori Silue; Anne-Marie Zeeman; Clemens Kocken; Didier Leroy; Benjamin Blasco; Emilie Rossignol; Thomas Rueckle; Dave Matthews; Jeremy N Burrows; David Waterson; Michael J Palmer; Pradipsinh K Rathod; Susan A Charman
Journal:  ACS Infect Dis       Date:  2016-10-04       Impact factor: 5.084

Review 3.  Are Antimalarial Hybrid Molecules a Close Reality or a Distant Dream?

Authors:  Drishti Agarwal; Rinkoo D Gupta; Satish K Awasthi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Synthesis and evaluation of 1,2,4-triazolo[1,5-a]pyrimidines as antibacterial agents against Enterococcus faecium.

Authors:  Huan Wang; Mijoon Lee; Zhihong Peng; Blas Blázquez; Elena Lastochkin; Malika Kumarasiri; Renee Bouley; Mayland Chang; Shahriar Mobashery
Journal:  J Med Chem       Date:  2015-05-12       Impact factor: 7.446

5.  Synthesis and antiplasmodial evaluation of 1H-1,2,3-triazole grafted 4-aminoquinoline-benzoxaborole hybrids and benzoxaborole analogues.

Authors:  Anu Saini; Sumit Kumar; Raghu Raj; Shefali Chowdhary; Mathieu Gendrot; Joel Mosnier; Isabelle Fonta; Bruno Pradines; Vipan Kumar
Journal:  Bioorg Chem       Date:  2021-02-16       Impact factor: 5.275

6.  Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

Authors:  Ramesh Gujjar; Alka Marwaha; Farah El Mazouni; John White; Karen L White; Sharon Creason; David M Shackleford; Jeffrey Baldwin; William N Charman; Frederick S Buckner; Susan Charman; Pradipsinh K Rathod; Margaret A Phillips
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

7.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.

Authors:  Margaret A Phillips; Ramesh Gujjar; Nicholas A Malmquist; John White; Farah El Mazouni; Jeffrey Baldwin; Pradipsinh K Rathod
Journal:  J Med Chem       Date:  2008-06-04       Impact factor: 7.446

8.  Synthesis, antifungal activity and CoMFA analysis of novel 1,2,4-triazolo[1,5-a]pyrimidine derivatives.

Authors:  Qiong Chen; Xiao-Lei Zhu; Li-Li Jiang; Zu-Ming Liu; Guang-Fu Yang
Journal:  Eur J Med Chem       Date:  2007-05-27       Impact factor: 6.514

9.  Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.

Authors:  Mohamed A Said; Wagdy M Eldehna; Alessio Nocentini; Alessandro Bonardi; Samar H Fahim; Silvia Bua; Dalia H Soliman; Hatem A Abdel-Aziz; Paola Gratteri; Sahar M Abou-Seri; Claudiu T Supuran
Journal:  Eur J Med Chem       Date:  2019-11-02       Impact factor: 6.514

10.  Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design.

Authors:  Francis W Muregi; Akira Ishih
Journal:  Drug Dev Res       Date:  2010-02       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.